Management

Jesper Wiklund, Chief Executive Officer
Jesper Wiklund brings 17 years of international commercial experience in the biotechnology and pharmaceutical industry to InDex Pharmaceuticals. Over the course of his career he has completed strategic transactions with an aggregate value exceeding USD 700 million. He has worked in the United States for Wyeth Pharmaceuticals and Elan Pharmaceuticals as well as in Germany for Evotec. He joins InDex from Swedish Orphan Biovitrum where he had responsibility for Business Development. Jesper Wiklund holds a B.S from St Mary's College of California and an MBA from Harvard Business School.

Per-Olof Gunnesson, Vice President Business Development & Finance
Per-Olof Gunnesson has more than 40 years experience from the pharmaceutical industry and the health care sector, including 27 years with the Astra Group where he worked in a number of different leading positions. He has broad experience from both research companies as well as from sales and marketing companies, which includes most functions of the company business. Per-Olof graduated from School of Economics in Gothenburg and has been with InDex since year 2002. He is board member of four other biotech companies.

Thomas Knittel, Chief Medical Officer
Thomas Knittel has over 15 years of clinical experience within gastroenterology as well as 13 years of experience in medical affairs and marketing management. Before joining InDex Pharmaceuticals, he held positions as Business Unit Director and Director of Sales and Marketing at Novo Nordisk for central Europe, as General Manager Pharmaceuticals at Harlan Laboratories, and as Vice President Corporate and Medical Affairs at Develogen AG. He has a Medical degree from the University of Mainz with a specialist training in internal medicine and gastroenterology. He is an Associate Professor in Internal Medicine and Gastroenterology at the University Clinic Goettingen. In addition, he has an MBA from Kellogg School of Management/WHU.

Pernilla Sandwall, Head of Clinical Operations
Pernilla Sandwall has more than 20 years of experience in clinical research operations. She joins InDex Pharmaceuticals from Merck & Co. Inc. (MSD), where she has worked both in the Swedish subsidiary and the U.S. headquarters, as well as regionally in Europe. She has experience in the field as CRA and project manager, as well as strategically as Clinical Research Manager. Her focus over the last years has been global patient recruitment, site selection strategies and execution. She also has experience in change management and Lean Six Sigma methodology. She has a Master of Science in Pharmacy from Uppsala University.

Oliver von Stein, Chief Scientific Officer and co-founder
Oliver von Stein carried out his molecular biology PhD studies at the Institute of Genetics in Karlsruhe, Germany, and held a postdoctoral position at Centre of Genomics and Bioinformatics at Karolinska Institutet, Stockholm. Before joining InDex Pharmaceuticals, he worked as a project leader of expression profiling at MediGene AG, Munich, Germany.